Skip to main content
. 2021 May 3;27(8):1173.e1–1173.e4. doi: 10.1016/j.cmi.2021.04.028

Table 2.

Factors associated with adequate antibody responsea by univariate and multivariate analyses

Variable Univariate
 Multivariate
Odds ratio (OR) 95%CI for OR p OR 95%CI for OR p
Younger age (per year decrease) 1.032 1.015 1.050 <0.001 1.038 1.018 1.059 <0.001
Female gender 0.764 0.468 1.248 0.282 — — — —
Time from transplantation (per year) 0.999 0.969 1.030 0.949 — — — —
Living donor 1.606 0.909 2.839 0.103 — — — —
eGFR (per mL/min/1.73 m2 increase) 1.025 1.014 1.037 <0.001 1.032 1.018 1.045 <0.001
eGFR <60 mL/min/1.73 m2 0.393 0.243 0.637 <0.001 — — — —
Diabetes mellitus 0.643 0.336 1.230 0.182 — — — —
Time from second vaccine dose (per day) 0.993 0.969 1.018 0.575 — — — —
BMI (per kg/m2) 0.995 0.946 1.047 0.852 — — — —
Lower mycophenolic acid dose (per 360 mg decrease) 1.763 1.422 2.187 <0.001 2.347 1.782 3.089 <0.001
Cyclosporine yes/no 0.928 0.381 2.263 0.870 — — — —
No mTOR inhibitor 0.907 0.397 2.072 0.816 2.870 1.058 7.781 0.038
Low CNI levelb 1.865 1.164 2.990 0.010 1.987 1.146 3.443 0.014
High-dose CSb 0.293 0.098 0.873 0.028 — — — —
Treatment with ATGb 0.463 0.126 1.696 0.245 — — — —

Odds ration > 1 indicates adequate association with antibody response. eGFR, estimated glomerular filtration rate; BMI, body mass index; mTOR, mammalian target of rapamycin; CNI, calcineurin inhibitors; ATG, antithymocyte globulin; CS, corticosteroids.

a

Adequate antibody response was defined as IgG ≥50 AU/mL using the SARS-CoV-2 IgG II Quant (Abbott©) assay.

b

Low CNI level was defined as ≤7 ng/mL for tacrolimus and ≤150 ng/mL for cyclosporine; high-dose CS was defined as intravenous methyl prednisolone (dose at least 250 mg) in the previous 6 months before the first vaccine dose; treatment with ATG was defined as any dosage in the last year before the first vaccine dose.